Advertisement

European Journal of Epidemiology

, Volume 29, Issue 8, pp 595–597 | Cite as

A pilot study of a genetic CJD risk factor (E200K) in the general Slovak population

  • Eva MitrováEmail author
  • Dana Kosorinová
  • Martin Gajdoš
  • Katarína Šebeková
  • Ivana Tomečková
Letter to the Editor

Creutzfeldt-Jakob disease (CJD) is a fatal, incurable human transmissible spongiform encephalopathy, or prion disease. Classical CJD has been recognised since the 1920s. CJD occurs in three forms : sporadic, of unknown origin, genetic, related to disease specific point mutations, insertions or deletions of the prion protein gene (PRNP) and iatrogenic (iCJD), caused by accidental transmission of the disease in the course of medical or surgical treatment. A new variant of CJD, which is causally related to bovine spongiform encephalopathy (BSE) was first described by Will et al. in 1996.

The risk of horizontal transmission of CJD has been confirmed in classical [1] as well as in variant CJD. Precautions and measures to prevent iCJD are focused mainly on clinical CJD patients, but a potential risk from preclinical cases, for example asymptomatic carriers of CJD-specific mutations of the PRNP, cannot be excluded. These carriers represent a “genetic CJD-risk group” in the general population.

Keywords

Creutzfeldt-Jakob disease E200K Carriers Prevention 

Notes

Acknowledgments

The work was supported by a grant from the EC “Protecting the food chain from prions: shaping European priorities through basic and applied research”, PRIORITY, No222887 and by grant from the EU Joint Programme “Neurodegenerative Disease Research” Biomarker based diagnosis of rapid progressive dementias, JPND- DEMTEST, 01ED1201A.

Conflict of interest

Authors declare no conflict of interest.

References

  1. 1.
    Duffy P, Wolf J, Collins G, DeVoe AG, Streeten B, Cowen D. Possible person -to -person transmission of Creutzfeldt- Jakob disease. N Engl J Med. 1974;290:692–3.PubMedGoogle Scholar
  2. 2.
    Kovács GG, Puopulo M, Ladogana A, Pocchiari M, Budka H, van Duijn C, et al. Genetic prion disease: the EUROCJD Experience. Hum Genet. 2005;118:166–74.PubMedCrossRefGoogle Scholar
  3. 3.
    Mitrova E, Belay G. Creutzfeldt-Jakob disease with E200 K mutation in Slovakia : characterization and development. Acta Virol. 2002;46:31–9.PubMedGoogle Scholar
  4. 4.
    Goldfarb L, Mitrová E, Brown P, Toh BK, Gajdusek DC. Mutation in codon 200 of scrapie amyloid protein gene in two clusters of CJD in Slovakia. The Lancet. 1990;336:514–5.CrossRefGoogle Scholar
  5. 5.
    Mitrová E, Černák A. Slivarichová D, Koščová, Černák M. Experience with preventive genetic testing of corneal donors. Cornea. 2011;30(7):987–90.PubMedCrossRefGoogle Scholar
  6. 6.
    Hill AF, Collinge J. Subclinical infection in humans and animals. Br Med Bull. 2003;66:161–70.PubMedCrossRefGoogle Scholar
  7. 7.
    Mitrová E. Some new aspects of CJD epidemiology in Slovakia. Eur J Epid. 1991;7:439–49.CrossRefGoogle Scholar
  8. 8.
    Collinge J, Palmer MS, Dryden AJ. Genetic predisposition to iatrogenic Creutzfeldt-Jakob disease. Lancet. 1991;337:1441–2.PubMedCrossRefGoogle Scholar
  9. 9.
    Mitrová E, Mayer V, Jovankovičová V, Slivarichová D, Wsólová L. CJD risk and PRNP polymorphism : necessity to revalue current data. Europ J Neurol. 2005;12:1–4.CrossRefGoogle Scholar
  10. 10.
    Kovács GG, László L, Bakos J, Mitrová E, Majtényi K. Increased incidence of genetic human prion disease in Hungary. Neurology. 2005;65:1–7.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2014

Authors and Affiliations

  • Eva Mitrová
    • 1
    • 2
    Email author
  • Dana Kosorinová
    • 1
    • 2
  • Martin Gajdoš
    • 1
    • 3
  • Katarína Šebeková
    • 4
  • Ivana Tomečková
    • 1
    • 2
  1. 1.Medical FacultySlovak Medical UniversityBratislavaSlovakia
  2. 2.Department of Prion DiseasesSlovak Medical UniversityBratislavaSlovakia
  3. 3.Department of Clinical and Experimental Pharmacology, Medical FacultySlovak Medical UniversityBratislavaSlovakia
  4. 4.Institute of Molecular Biomedicine, Medical FacultyComenius UniversityBratislavaSlovakia

Personalised recommendations